A large-scale genomic study involving nearly 14,250 lung cancer patients has revealed that age is not merely a demographic footnote in cancer care, but a shaping force in tumor biology itself. Younger patients with non-small cell lung cancer were found significantly more likely to carry genetic mutations that existing precision therapies can target, while older patients' tumors followed a distinct molecular grammar — more KRAS mutations, heavier mutational burden, and different immune markers. Presented this September at the World Conference on Lung Cancer in Seoul, the findings invite medicin